Abstract
Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Current Pharmaceutical Biotechnology
Title:Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects
Volume: 15 Issue: 7
Author(s): Francisca Araujo, Neha Shrestha, Pedro L. Granja, Jouni Hirvonen, Hélder A. Santos and Bruno Sarmento
Affiliation:
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Abstract: Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Export Options
About this article
Cite this article as:
Araujo Francisca, Shrestha Neha, Granja L. Pedro, Hirvonen Jouni, Santos A. Hélder and Sarmento Bruno, Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects, Current Pharmaceutical Biotechnology 2014; 15 (7) . https://dx.doi.org/10.2174/1389201015666140915150312
DOI https://dx.doi.org/10.2174/1389201015666140915150312 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD)
Current Pharmaceutical Design Criteria for Creating and Assessing Mouse Models of Diabetic Neuropathy
Current Drug Targets Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Current Diabetes Reviews Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Maternal Sodium Valproate Exposure Alters Neuroendocrine-Cytokines and Oxido-inflammatory Axes in Neonatal Albino Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Proteomic Analysis of the Vitreous Body in Proliferative and Non-Proliferative Diabetic Retinopathy
Current Proteomics Knowledge and Awareness of Oral Manifestations of Diabetes Mellitus and Oral Health Assessment among Diabetes Mellitus Patients- A Cross Sectional Study
Current Diabetes Reviews Role of Adipocytokines in Hepatic Fibrosis
Current Pharmaceutical Design Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Almonds: A Source of Healthy Molecules or a Risk of Aflatoxins Human Exposure?
Current Nutrition & Food Science The Usefulness of Phalangeal Quantitative Ultrasound in the Assessment of Skeletal Status in Children and Adolescents
Current Medical Imaging Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State
Vascular Disease Prevention (Discontinued) Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Current Signal Transduction Therapy The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Diabetes Vaccinations: An Overview
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery